Dogwood Therapeutics (DWTX) Total Current Liabilities (2020 - 2026)

Dogwood Therapeutics (DWTX) has reported Total Current Liabilities for 7 consecutive years, with $2.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Current Liabilities fell 0.77% year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $2.6 million (down 0.77% YoY), while the FY2025 annual figure was $3.1 million, down 3.69% from the prior year.
• Total Current Liabilities slipped to $2.6 million in Q1 2026 per DWTX's latest filing, from $3.1 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $3.2 million in Q4 2024 and bottomed at $358548.0 in Q4 2023.
• Historically, Total Current Liabilities has averaged $1.6 million across 5 years, with a median of $1.6 million in 2022.
• Annual changes were most pronounced in 2023 — Total Current Liabilities sank 72.6% — and 2024, when it soared 785.89%.
• Dogwood Therapeutics' Total Current Liabilities stood at $1.0 million in 2022, then tumbled by 65.63% to $358548.0 in 2023, then jumped by 785.89% to $3.2 million in 2024, then declined by 3.69% to $3.1 million in 2025, then decreased by 16.32% to $2.6 million in 2026.
• Business Quant data shows DWTX's Total Current Liabilities at $2.6 million in Q1 2026, $3.1 million in Q4 2025, and $2.6 million in Q3 2025.